Despite the small sample size, this investigation introduces a viable therapeutic alternative for patients with advanced HER2-altered NSCLC, particularly through a regimen incorporating RC48 in conjunction with platinum-based chemotherapy, with or without bevacizumab. Here, ERBB2 is linked to non-small cell lung carcinoma.